

1.13 Galantamine hydrobromide versus placebo

Figure 141: Fatigue: fatigue on VAS at 2 weeks




Figure 142: Cognitive function: memory on VAS at 2 weeks




Figure 143: Pain: myalgia on VAS at 2 weeks




Figure 144: Sleep quality: sleep disturbance on VAS at 2 weeks




Figure 145: Adverse events: AEs dizziness on VAS at 2 weeks




Figure 146: Return to school/work: work capacity/satisfaction on VAS at 2 weeks




Figure 147: Symptom scales: clinical global impression score, no change or worse at 20 weeks

